Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.78 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.78 |
| ▸ | ITGAV | P06756 | 1/20 | 0.78 |
| ▸ | LDLR | P01130 | 12/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 12/20 | 0.56 |
| ▸ | TSLP | Q969D9 | 5/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
| ▸ | MC1R | Q01726 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL29398425 | 0.97 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL15781 | 0.97 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL8284422 | 0.97 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL571287 | 0.97 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753462 | 0.96 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL7107217 | 0.96 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL1890434 | 0.95 | ITGB3 (0.80) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL24433365 | 0.95 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL22193885 | 0.95 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753468 | 0.93 | ITGB3 (0.76) | ITGB3ITGAVITGA2BLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850285-B2 | Process for preparing eptifibatide | LAURUS LABS LIMITED (IN) | 2017-12-26 | — | — | US | disclosed |
| US-20160017002-A1 | Process for Preparing Eptifibatide | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | disclosed |
| US-9156885-B2 | Process for preparing eptifibatide | LAURUS LABS PRIVATE LTD. (IN) | 2015-10-13 | — | — | US | disclosed |
| US-20140163203-A1 | PROCESS FOR PREPARING EPTIFIBATIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2014-06-12 | — | — | US | disclosed |
| WO-2013014527-A1 | PROCESSES FOR PREPARING EPTIFIBATIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2013-01-31 | — | — | WO | disclosed |
| US-20100240865-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | TOVI AVI | 2010-09-23 | — | — | US | disclosed |
| US-20100137559-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | TOVI AVI | 2010-06-03 | — | — | US | disclosed |
| EP-1709065-B1 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | NOVETIDE LTD (IL) | 2010-06-02 | — | — | EP | disclosed |
| EP-2163558-A2 | A Counterion Exchange Process for Peptides | Novetide Ltd. (IL) | 2010-03-17 | — | — | EP | disclosed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1511761-B1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | NOVETIDE LTD (IL) | 2006-08-02 | — | — | EP | disclosed |
| US-20060148699-A1 | Counterion exchange process for peptides | TEVA PHARMACEUTICALS USA, INC. | 2006-07-06 | — | — | US | disclosed |
| EP-1511761-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | Novetide Ltd. (IL) | 2005-03-09 | — | — | EP | disclosed |
| US-20040249121-A1 | Process for production of cyclic peptides | NOVETIDE, LTD. (IL) | 2004-12-09 | — | — | US | disclosed |
| WO-2004092202-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | NOVETIDE, LTD. (IL) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148699-A1 | Counterion exchange process for peptides | VIP, NPPA, SLC26A3 | ITGB3 3515/4885ITGA2B 4403/4885ITGAV 3286/4885 |
| US-20140163203-A1 | PROCESS FOR PREPARING EPTIFIBATIDE | PTGER4, VIP, TBXA2R | ITGB3 863/4885ITGA2B 824/4885ITGAV 1188/4885 |
| US-20100137559-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | VIP, NPPA, IAPP | ITGB3 4512/4885ITGA2B 4607/4885ITGAV 3925/4885 |
| US-20160017002-A1 | Process for Preparing Eptifibatide | PTGER4, VIP, TBXA2R | ITGB3 863/4885ITGA2B 824/4885ITGAV 1188/4885 |
| US-20100240865-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | VIP, NPPA, IAPP | ITGB3 4512/4885ITGA2B 4607/4885ITGAV 3925/4885 |
| US-20040249121-A1 | Process for production of cyclic peptides | VIP, NPPA, IAPP | ITGB3 4512/4885ITGA2B 4607/4885ITGAV 3925/4885 |
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | ITGB3 4019/4885ITGA2B 4596/4885ITGAV 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.